· Published by Health Canada · Official notice
Notice about Health Canada advisories
October 25, 2006
To: Hospital Chief of Medical Staff
Please distribute to the relevant Departments of Emergency, Pediatrics, Anaesthesia, Surgery, Intensive Care, Medicine and other involved professional staff and post this NOTICE in your institution.
Subject: Syringe Infusion Pumps - Risk of Delay in Detection of Downstream Occlusion
Health Canada is aware of international reports of delays in occlusion detection associated with the use of syringe pumps and wishes to alert healthcare professionals to this safety information.
Syringe infusion pumps are devices used to provide a continuous intravenous administration of medication. They are mostly used in anaesthesiology, intensive care and emergency medicine to deliver small volumes of highly potent medications. They offer many advantages over larger volumetric infusion pumps such as reduced size, lower cost and ease of operation.
Syringe infusion pumps are typically equipped with a pressure sensor at the syringe pump plunger or drive mechanism as well as an occlusion alarm with several pressure settings. When the internal system pressure surpasses the alarm occlusion threshold pre-selected by the operator, the device will alarm and alert users to a possible occlusion event. Any lag period in the detection of downstream occlusion places the patient at risk of serious injury, possibly from the underdelivery of critical medication or the inadvertent delivery of a bolus dose if the occlusion is not carefully corrected.
Cases reported in the medical literature suggest that delays in detecting an occlusion are often associated with the use of large syringe sizes combined with infusions at low flow rates. The length of tubing used and the compliance of the tubing also appear to play a role in the time required for the system pressure to build up sufficiently to trigger the alarm.
To minimize any delay in detecting an occlusion, Health Canada recommends the following:
Managing marketed health product-related adverse incidents depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse incidents are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious or unexpected adverse incidents in patients using syringe infusion pump should be reported to the marketing authorization holder or to Health Canada at the following address:
Health Products and Food Branch Inspectorate
HEALTH CANADA
Address Locator: 2003D
Ottawa, Ontario K1A 0K9
Tel: The Inspectorate Hotline 1-800-267-9675
The Reporting Form and Guidelines can be obtained from the Health Canada web site.
For other inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
Email: MHPD_DPSC@hc-sc.gc.ca
Tel: (613) 954-6522
Fax: (613) 952-7738
References: